|
Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update 13.11.2026 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled Expected in the First Half of 2027 – – Executive Leadership Team Further Strengthened with Appointments of Chief Data and Digital Officer and Chief People Officer to Support Regulatory and Commercial Readiness – NEW YORK, November 13, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. “As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history,” said Erik Lundgren, Chief Executive Officer of Immunic. “We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS. We believe vidofludimus calcium has the potential to address mechanisms associated with both the neurodegenerative and inflammatory drivers of the disease, which, if confirmed in our Phase 3 trials, could offer a differentiated treatment option in MS. Subject to positive ENSURE results, we are preparing for a potential New Drug Application (NDA) submission in relapsing MS, while we continue to advance our Phase 3 program in progressive MS.” “We were fortunate to present exciting data in four posters at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, which added complementary clinical and mechanistic evidence supporting the potential of vidofludimus calcium to address existing unmet needs in MS,” added Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic. “Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive. In parallel, the Phase 2 CALLIPER data along with the insights shared by leading MS experts at our two recent R&D Days support the rational for our Phase 3 PROTECT-MS trial in progressive MS, with initiation ongoing and first-patient-enrolled expected in the first half of 2027.” Third Quarter 2026 and Subsequent Highlights
Anticipated Clinical Milestones
Financial and Operating Results Total Operating Expenses for the three and nine months ended September 30, 2026 were $43.4 million and $111.9 million, respectively. Included in these results are $13.9 million and $25.2 million, respectively, of non-cash charges, primarily related to stock compensation expense. Research and Development (R&D) Expenses were $23.9 million for the three months ended September 30, 2026, as compared to $20.0 million for the three months ended September 30, 2025. The $3.9 million increase reflects (i) a $1.9 million increase in personnel expenses, $0.6 million of which was related to non-cash stock compensation, (ii) a $1.4 million increase for vidofludimus calcium drug supply, (iii) a $2.9 million increase for NDA readiness activities, (iv) a $0.3 million increase due to drug-drug interaction studies in support of a potential NDA filing and (v) a $0.2 million increase related to costs across numerous categories, partially offset by (vi) a $1.8 million decrease related to the ENSURE clinical trials and (vii) a $1.0 million decrease related to the CALLIPER clinical trial. For the nine months ended September 30, 2026, R&D expenses were $75.5 million, as compared to $62.9 million for the nine months ended September 30, 2025. The $12.6 million increase reflects (i) a $7.4 million increase in personnel expenses, $4.4 million of which was related to non-cash stock compensation, (ii) a $4.5 million increase for vidofludimus calcium drug supply, (iii) a $4.1 million increase for NDA readiness activities, (iv) a $3.9 million increase due to drug-drug interaction studies in support of a potential NDA filing and (v) a $1.7 million increase related to costs across numerous categories, partially offset by (vi) a $5.2 million decrease related to the ENSURE clinical trials and (vii) a $3.8 million decrease related to the CALLIPER clinical trial. General and Administrative (G&A) Expenses were $19.4 million for the three months ended September 30, 2026, as compared to $6.0 million for the same period ended September 30, 2025. The $13.4 million increase was due to (i) an $11.0 million increase related to personnel expenses, of which $9.7 million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $1.3 million increase in legal and consultancy expenses, (iii) a $0.6 million increase in pre-commercial marketing expenses and (iv) a $0.5 million increase in related costs across numerous categories. For the nine months ended September 30, 2026, G&A expenses were $36.4 million, as compared to $17.0 million for the same period ended September 30, 2025. The $19.4 million increase was due to (i) a $15.2 million increase related to personnel expenses, of which $13.2 million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $2.3 million increase in legal and consultancy expenses, (iii) a $1.2 million increase in pre-commercial marketing expenses and (iv) a $0.7 million increase in related costs across numerous categories. Interest Income was $1.1 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September 30, 2025. The $0.7 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement. For the nine months ended September 30, 2026, interest income was $3.1 million, as compared to $0.8 million for the same period ended September 30, 2025. The $2.3 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement. Other Income (Expense) was ($0.03 million) for the three months ended September 30, 2026, as compared to ($0.01 million) for the same period ended September 30, 2025. For the nine months ended September 30, 2026, Other Income (Expense) was ($0.2 million), as compared to $1.2 million for the same period ended September 30, 2025. The $1.4 million decrease was primarily attributable to (i) $1.0 million of grant income from the German Federal Ministry of Finance recognized in the first quarter of 2025 and no grant income in 2026 and (ii) a $0.4 million decrease across various categories. Net Loss for the three months ended September 30, 2026, was approximately $42.3 million, or $0.99 per basic and diluted share, based on 42,797,370 weighted-average common shares outstanding, compared to a net loss of approximately $25.6 million, or $1.32 per basic and diluted share, based on 19,389,776 weighted-average common shares outstanding for the same period ended September 30, 2025. Net loss for the nine months ended September 30, 2026, was approximately $109.0 million, or $2.83 per basic and diluted share, based on 38,508,964 weighted-average common shares outstanding, compared to a net loss of approximately $77.9 million, or $5.45 per basic and diluted share, based on 14,281,149 weighted-average common shares outstanding for the same period ended September 30, 2025. Cash and Cash Equivalents as of September 30, 2026 were $132.0 million. Based on its current operating plan, Immunic expects that these funds will be sufficient to fund its operations into late 2027. About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com. Vidofludimus calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority for any indication in any jurisdiction. Its safety and efficacy have not been established. Any clinical, biomarker, or preclinical findings described reflect investigational data and are not intended to suggest that vidofludimus calcium is safe or effective for any use. Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the nature, strategy and focus of the company; the development and commercial potential of Immunic’s product candidates, including their potential to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the expected timing and results of the Phase 3 ENSURE trials; the timing of a Phase 3 trial of vidofludimus calcium in progressive multiple sclerosis; the timing of potential NDA submission and regulatory approval; expectations regarding the capitalization, resources and ownership structure of the company; the expected sufficiency of Immunic’s cash and cash equivalents; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risk that top-line results from the ENSURE-1 and ENSURE-2 trials may be delayed, negative, or fail to meet their primary or secondary endpoints; the risk that results of earlier, post-hoc, exploratory, open-label or preclinical analyses may not be predictive of, or confirmed in, subsequent controlled clinical trials or accepted by regulatory authorities; the risk that the initiation, or first-patient enrollment in, of the Phase 3 progressive MS trial, or the submission or approval of an NDA, may be delayed or may not occur; risks related to drug development and the regulatory review process; the risk that Immunic’s cash and cash equivalents may be insufficient to fund operations for the period anticipated, including due to changes to its operating plan, and Immunic’s need to raise additional capital; increasing inflation, tariffs and macroeconomic trends; impacts of the Ukraine – Russia conflict and the conflict in the Middle East on clinical trials; changes to the size of the target markets for the company’s product candidates; the protection and market exclusivity provided by Immunic’s intellectual property; and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, Inc. US IR Contact US Media Contact
Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Author Archives:
Inaugural Future of Oncology Summit Brings Together Leaders to Accelerate Cancer Innovation
Inaugural Future of Oncology Summit Brings Together Leaders to Accelerate Cancer Innovation
Inaugural Future of Oncology Summit Brings Together Leaders to Accelerate Cancer Innovation
More than 500 leaders gathered in New Haven for discussions spanning artificial intelligence, emerging therapies, and investment in oncology
NEW HAVEN, Conn.–(BUSINESS WIRE)–On November 9–10, the inaugural Future of Oncology Summit brought together over 500 leaders from academia, biotechnology, pharmaceuticals, investment, and the broader oncology ecosystem at 101 College Street in New Haven. The two-day event featured more than 70 speakers, including keynote speakers Clifford Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Annie Lamont, co-founder and managing partner of Oak HC/FT, as well as remarks from Connecticut Governor Ned Lamont and Department of Economic and Community Development (DECD) Commissioner Daniel O’Keefe.
The Summit, co-hosted by Yale Cancer Center (YCC) and BioCT, presented forward-looking insights spanning artificial intelligence, emerging therapies, and strategic investments—all aimed at advancing the next generation of cancer research. Central to this landmark gathering was a shared commitment to fostering collaboration across disciplines to accelerate progress in oncology, as described by Summit co-chairs Eric Winer, MD, director of YCC and president and physician-in-chief of Smilow Cancer Hospital, and David Scheer, BioCT board co-chair and president of Scheer & Company, Inc.
“The Future of Oncology Summit showed what’s possible when the people who discover new treatments, the people who build companies around them, the people who invest in them, and the people who use them to improve lives all come together in one room,” said Winer and Scheer. “The energy over these two days makes it clear that Yale Cancer Center and the Connecticut life science ecosystem are poised for leadership in the next era of cancer research and care. This is just the beginning, and we look forward to turning these conversations into progress for patients.”
The Summit’s Organizing Committee included Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology, Yale School of Medicine; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Kat Kayser-Bricker, PhD, Vice President, Integrated Discovery Portfolio, Johnson & Johnson; and Janie Merkel, PhD, Corporate Strategy Officer for Health & Life Sciences, Yale Ventures.
In his opening remarks, Governor Lamont addressed the researchers, clinicians, and biotech leaders gathered at the Summit, emphasizing his commitment to providing the certainty and support that enable them to advance cancer innovation in Connecticut.
“My job is to do everything possible to foster the ecosystem you need to continue to grow and innovate and expand,” said Governor Lamont. He pointed to several priorities for sustaining that environment, such as maintaining fiscal stability to attract investment, cultivating vibrant, affordable cities to retain young researchers and entrepreneurs, and leveraging Connecticut’s strengths in manufacturing and emerging technologies like quantum to drive innovation.
Commissioner O’Keefe expanded on how Connecticut’s technological strengths could help accelerate scientific breakthroughs, including in oncology. “Where we have a real comparative advantage is taking emerging technologies and applying them in our core industries. When reporters ask me to give a real-world example of what problems quantum can solve, I say the cure for cancer, and I’m not kidding.”
The transformative potential of artificial intelligence was a central theme throughout the Summit, particularly its ability to democratize access across the oncology landscape, from unlocking vast amounts of research data to making existing treatments more widely available.
“What’s happening with AI should not be seen as a threat to the high-quality practice of oncology,” said Hudis during his keynote. “It should be seen as the tool that it inevitably will be. It should be seen as an elevator of quality of care. It should be seen as a democratizer of access. And I think if we take that approach, we can be very excited for a much brighter future.”
In her fireside chat, Annie Lamont echoed this enthusiasm for widening access to care. “What’s really exciting right now is that the democratization of data and information can cause everyone in the U.S. to have the ability to be diagnosed quickly and correctly then figure out how to get into treatment. It’s one thing to create the drugs and treatments; it’s another to make sure everyone gets access to them.”
The Summit also explored the role of investment and strategic partnerships in drug development—including the potential payoff of pursuing alternative approaches. During the panel Case Study for a Transformative Deal in Oncology, speakers highlighted how Halda Therapeutics’ RIPTAC molecule, once considered its “Plan B,” went on last month to demonstrate a 75% tumor response rate for patients with advanced prostate cancer. Now part of Johnson & Johnson’s drug pipeline following its $3 billion acquisition of Halda last year, the program underscores the importance of trust between emerging biotech companies and major pharmaceutical partners in bringing ambitious innovations forward.
“There was something uniquely creative about Halda’s beginnings in a tiny lab space, where ideas moved quickly and everyone was deeply connected to the mission of inventing new science,” said Kayser-Bricker, who previously served as Chief Scientific Officer at Halda. “J&J’s acquisition reflects a real trust in the innovation and culture we built, and it now gives us the opportunity to bring that approach to a much larger scale and, ultimately, to many more patients.”
Halda’s story reflects a broader transformation underway in oncology, as once-unimaginable therapies move closer to clinical practice. Yet as every discussion throughout the Summit reinforced, the true measure of progress remains its positive impact on people’s lives.
“We are at an exciting inflection in oncology, where targets once considered undruggable are becoming druggable, and tumor vaccines are opening new possibilities,” said Jodie Gillon, President & CEO of BioCT. “Yet as these innovations advance at breakneck speed, it’s imperative that we ensure patients have access to the testing, technology, and medicines they may benefit from. Everyone in the room has a role to play in making that happen.”
About BioCT
BioCT is the life sciences trade organization for the state of Connecticut. The not-for-profit organization serves as the voice of more than 300 member companies. Its mission is to catalyze and accelerate growth in the life sciences with the goal of improving human health, by fostering a rich, innovative ecosystem and promoting Connecticut as a preferred destination for life sciences exploration and innovation. To learn more, visit https://bioct.org.
Contacts
Gabrielle Wasco
gwasco@bioct.org
(508) 231-6846
Ontada Advances the Intelligent Medical Record with Integrated AI Capabilities for iKnowMed
Ontada Advances the Intelligent Medical Record with Integrated AI Capabilities for iKnowMed
Ontada Advances the Intelligent Medical Record with Integrated AI Capabilities for iKnowMed
New AI-powered capabilities help oncology providers spend less time on administrative work and more time focused on patient care
BOSTON–(BUSINESS WIRE)–Ontada®, a McKesson business dedicated to transforming community oncology through technology, data and insights, today announced that new artificial intelligence capabilities are now available to all iKnowMed® customers, including practices in The US Oncology Network and independent practices across the country. Designed to help oncology practices improve productivity, streamline everyday workflows and reduce administrative burden, the new capabilities also advance Ontada’s broader Intelligent Medical Record strategy to bring greater intelligence into the technology providers and care teams already use.
The new offering brings several connected AI capabilities together in one platform: ambient documentation that helps draft visit notes, summaries designed to make it easier to review patient charts and visits, smart coding that suggests appropriate diagnosis codes based on visit context, a Practice Assistant that supports provider and practice questions, clinical decision-making and workflow guidance, and dictation that converts spoken words into text wherever the cursor is placed. Bringing these capabilities together provides practices with a more unified experience rather than requiring providers and care teams to rely on separate tools for individual tasks.
“We believe AI can deliver greater value when it is connected to the technology and workflows oncology practices already use, rather than operating as another standalone solution,” said Rob Helton, chief product officer, Ontada. “By unifying these capabilities into iKnowMed workflows clinicians use every day, practices can immediately benefit while creating the foundation for a much broader Intelligent Medical Record, one that helps clinicians work more efficiently, helps practices operate more effectively and continually becomes smarter as new capabilities are added.”
Ontada developed these capabilities in collaboration with Commure, a healthcare company that delivers AI application solutions to electronic health record platforms and providers. Unlike standalone AI tools focused on a single task, iKnowMed brings documentation, summarization, coding, practice assistance and dictation into a single workflow within a broader technology platform for oncology practices.
The launch follows real-world use by early adopters at select community oncology practices. Their input helped shape how the technology comes to life within iKnowMed, reflecting the needs and workflows of oncology providers and care teams. This collaboration brings together Commure’s broader healthcare AI capabilities with Ontada’s deep understanding of community oncology and the practices it serves.
“These new capabilities are exciting because they can help address real clinical pain points, including preparing for visits, documenting care and reducing routine follow-up work,” said Brian Heller, MD, president, Southern Cancer Center. “Just as important, this opens the door for what is possible next: a more integrated experience that continues to improve how physicians, care teams and practices work together on behalf of patients.”
The offering is part of Ontada’s broader Intelligent Medical Record strategy to evolve iKnowMed beyond a traditional system of record into a system of intelligence and action. Over time, Ontada plans to bring AI, data, clinical workflows and connected partner solutions into a more unified oncology experience, helping practices simplify their technology environment and expanding the value iKnowMed delivers over time.
About Ontada®
Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the belief that precise insights—delivered exactly at the point of need—can save more patients’ lives. Ontada connects the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by leading life sciences companies. For more information, visit ontada.com.
About McKesson Oncology & Multispecialty
Our Oncology & Multispecialty segment delivers a portfolio of integrated solutions that support patient care by accelerating drug development, expanding access to high-quality care close to home and ensuring life-saving therapies reach the patients who need them most. We provide practice management, technology solutions, specialty drug distribution, clinical trial and group purchasing services, along with pharmacy solutions for community-based oncology practices and multispecialty providers in retina and ophthalmology. We partner behind the scenes with healthcare providers in local communities, supporting their operations so that they can stay focused on who matters most – patients.
Contacts
Media Contact
Sarah Neason Dobbs
945-230-4579
Sarah.Neason@McKesson.com
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
- A single dose of ZL-1503, across dose levels from 200 to 1,000 mg, produced near-complete (≥90%) inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least 3 months
- Extended serum half-life of approximately 40 to 50 days, with dose-proportional exposure, supports the potential for less frequent maintenance dosing
- ZL-1503 was well tolerated across all doses, with no serious adverse events or anti-drug antibodies detected
- Data from the Part B trial cohort evaluating multiple ascending doses of ZL-1503 in patients with moderate-to-severe atopic dermatitis expected in the first half of 2027
- ZL-1503 is a novel IL-13/IL-31Rα bispecific antibody devised to address both skin inflammation and itch through two clinically validated pathways
- Investor conference call and webcast to discuss ZL-1503 data and clinical program is scheduled for Friday, November 13 at 8:00 a.m. ET / 9:00 p.m. HKT
SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally discovered, long-acting IL-13/IL-31 receptor alpha (Rα) bispecific antibody. Findings from the study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting.
The Phase 1 data from healthy volunteers demonstrated rapid and sustained inhibition of the IL-13 pathway, with at least 90% inhibition of phosphorylated STAT6 (pSTAT6), an atopic dermatitis- (AD) related signaling biomarker, through Week 12 following a single dose of 200 mg or higher. Treatment also resulted in reductions in downstream inflammatory biomarkers, including TARC and CCL26, supporting broad modulation of type 2 inflammatory signaling.
Pharmacokinetic results demonstrated dose-proportional exposure and an extended half-life of approximately 40 to 50 days, nearly twice as long as that of several approved anti-IL-13 and anti-IL-31 biologics. These findings support further evaluation of extended maintenance dosing intervals, with a target of once every 12 weeks. ZL-1503 was well tolerated across all evaluated dose levels, with no serious adverse events, dose-limiting toxicities, or detectable anti-drug antibodies.
“These first-in-human findings reinforce the potential of ZL-1503 as a differentiated, first-in-class treatment option for patients with atopic dermatitis,” said Rafael G. Amado, M.D., President and Head of Global Research and Development at Zai Lab. “By combining two clinically validated mechanisms in a single, half-life-extended bispecific, ZL-1503 has the potential to control inflammation, deliver rapid and durable itch relief, and enable less frequent dosing. We have already initiated the next phases of this global study, which is evaluating the pharmacokinetics, safety, and initial efficacy of repeated doses of ZL-1503 in patients with moderate-to-severe atopic dermatitis and a subcutaneous formulation.”
ZL-1503 is a novel, long-acting, investigational bispecific antibody being developed for moderate-to-severe atopic dermatitis and other IL-13- and IL-31-driven diseases. IL-13 and IL-31 are key mediators of AD pathogenesis. IL-13 promotes type 2 inflammation and tissue remodeling, while IL-31 drives pruritus (itch) and amplifies local immune responses. Together, these cytokines perpetuate the itch-scratch-inflammation cycle that contributes to the development and persistence of AD and related conditions. ZL-1503 disrupts this cycle, and it incorporates serum half-life extension technology to prolong systemic exposure, potentially enabling less frequent dosing. Preclinical data presented earlier this year demonstrated that ZL-1503 provided rapid itch relief and significantly reduced inflammation in animal models of atopic diseases.
The ongoing randomized, double-blind, placebo-controlled Phase 1/1b trial (NCT07235384) is evaluating single ascending doses of ZL-1503 in healthy volunteers and multiple ascending doses in adults with moderate-to-severe atopic dermatitis. The findings presented at ACAAI 2026 include pharmacokinetic (PK) data following single-dose administration, pharmacodynamic (PD) assessment of AD-related biomarkers across ZL-1503 dose levels ranging from 50 to 1,000 mg or placebo, and preliminary safety and immunogenicity data from a total of 48 healthy volunteers.
Key results include:
- Sustained pharmacodynamic activity: At Week 12, ZL-1503 achieved at least 90% inhibition of pSTAT6 at doses ranging from 200 to 1,000 mg. Reductions were also observed in circulating type 2 inflammatory biomarkers associated with AD, including TARC, CCL26, and IgE.
- Favorable pharmacokinetic and immunogenicity profiles: ZL-1503 demonstrated dose-proportional exposure. As of the data cut-off, no anti-drug antibodies were detected in participants who received ZL-1503.
- Encouraging safety and tolerability: ZL-1503 was well tolerated at all evaluated dose levels, with no dose-limiting toxicities, treatment-emergent adverse events (TEAEs) leading to study drug interruption, or serious adverse events (SAEs) reported. Most TEAEs were mild and were associated with study procedures or intercurrent illnesses.
Data from the Part B trial cohort evaluating multiple ascending doses of ZL-1503 in patients with moderate-to-severe atopic dermatitis are expected in the first half of 2027. Zai Lab has also completed enrollment in an intravenous-to-subcutaneous bioavailability bridging study of ZL-1503. Initial data from this Phase 1 trial are expected in 2027.
ACAAI 2026 ZL-1503 poster details:
Title: Preliminary Results From The First-In-Human, Single Ascending Dose Study Of ZL-1503, A Half-Life-Extended Anti-IL-13/IL-31Rα Bispecific Antibody, In Healthy Volunteers
Presenter: Henry Wu, Zai Lab
Date/Time: Friday, November 13, 2026; 2:50 p.m. Mountain Time
ePoster ID: R376
Abstract Number: 8201
Details regarding the webcast and conference call are as follows:
Date/Time: Friday, November 13, 2026, at 5:00 a.m. PT / 8:00 a.m. ET / 9:00 p.m. HKT
Registration available at:
Webcast presentation (preferred): https://edge.media-server.com/mmc/p/a7xzskym
Dial-in: https://register-conf.media-server.com/register/BI3cdc6b1d6502458aaafbca52f735d28d
Presenter: Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab
About ZL-1503
ZL-1503 is a potential first-in-class bispecific antibody targeting IL-13 and IL-31Rα, developed through Zai Lab’s in-house discovery engine. It is devised to simultaneously suppress both inflammatory and pruritogenic (itch-causing) pathways implicated in atopic dermatitis (AD) and other IL-13 and IL-31-driven diseases, potentially offering a faster onset of action and greater efficacy than single-pathway inhibition.
ZL-1503 is currently being evaluated in an ongoing global Phase 1/1b clinical trial evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy. This clinical advancement is supported by preclinical studies demonstrating the ability of ZL-1503 to simultaneously suppress inflammatory and pruritogenic pathways implicated in AD.
About Zai Lab
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.linkedin.com/company/zai-lab or https://x.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating to our future expectations, plans, and prospects for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing ZL-1503 and the potential treatment of atopic dermatitis and other immune-mediated inflammatory diseases. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC’s website at www.SEC.gov.
Contacts
For more information, please contact:
Investor Relations:
Christine Chiou / Cyan Liu
+1 (917) 886-6929 / +86 195 3130 8895
christine.chiou1@zailaboratory.com / cyan.liu@zailaboratory.com
Media:
Shaun Maccoun / Xiaoyu Chen
+1 (857) 270-8854 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com/ xiaoyu.chen@zailaboratory.com
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Some children up to 24 months of age remain vulnerable to severe RSV in their second RSV season – underscoring the importance of preventive options for this at-risk population
RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season. The CHMP recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway, and a final decision is expected in the next two months.
ENFLONSIA was first approved by the U.S. FDA in June 2025 and by the European Commission in April 2026 for the prevention of RSV LRTD in infants born during or entering their first RSV season. ENFLONSIA is the first and only preventive option against RSV LRTD administered to infants without the need for weight-based dosing. As previously announced, the FDA accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA to expand its indication to include prevention of RSV LRTD in children under two years of age at increased risk for severe RSV disease through their second RSV season and set a Prescription Drug User Fee Act (PDUFA), or target action, date of March 22, 2027.
“For some children, the risk of severe RSV does not end after their first RSV season and they remain at increased risk for serious cases of RSV-related bronchiolitis or pneumonia that can require hospitalization,” said Dr. Macaya Douoguih, vice president, Therapeutic Area Head, Global Clinical Development, Merck Research Laboratories. “The positive CHMP opinion is an important step toward bringing ENFLONSIA to children in the European Union who remain at increased risk, helping protect them during their second RSV season.”
Certain children, including those born with chronic lung disease, congenital heart disease, or early or moderately preterm birth with certain risk conditions, remain vulnerable to severe RSV disease during their second RSV season.
The CHMP opinion is supported by results from the Phase 3 SMART trial (MK-1654-007) (NCT04938830), which were presented at RSVVW’26, the 9th conference of the Respiratory Syncytial Virus Foundation (ReSViNET), in February 2026, published in the New England Journal of Medicine in September 2025 (interim RSV season 1 results) and JAMA Pediatrics in July 2026 (full results).
ENFLONSIA is approved in more than 55 countries worldwide, including the United States, Canada, China, Japan, and the European Union, for use in infants during their first RSV season. Regulatory filings are underway for approval in additional countries globally, as well as for the expansion of the indication to include eligible children under two years of age in the United States and countries where ENFLONSIA is already approved.
About the Phase 3 SMART trial
The SMART trial (MK-1654-007) (NCT04938830) was a Phase 3, randomized, partially-blind, palivizumab-controlled, multicenter study to evaluate the safety, efficacy and pharmacokinetics of ENFLONSIA in infants and children at increased risk for severe RSV disease over two RSV seasons. The trial enrolled early (<29 weeks gestational age [GA]) or moderate preterm infants (≥29 to ≤35 weeks GA) and infants with chronic lung disease (CLD) of prematurity or congenital heart disease (CHD) of any GA.
In RSV season 1, participants were randomized 1:1 to receive either a 105 mg dose of ENFLONSIA (n=502) or monthly palivizumab (n=501) by intramuscular (IM) injection. In RSV season 2, eligible participants (children under 2 years of age with CLD, CHD or early or moderate preterm birth with certain risk conditions) received an additional open-label 210 mg dose of ENFLONSIA by IM injection (n=276). Nearly all participants (99%) who received ENFLONSIA in RSV season 2 had CLD (n=229) or CHD (n=43).
About RSV globally
Respiratory syncytial virus (RSV) is a contagious virus that causes widespread seasonal infections and can lead to serious respiratory conditions such as bronchiolitis and pneumonia. As a leading cause of hospitalization among infants globally, there is persisting unmet need for RSV preventive options for both healthy and high-risk infants during their first RSV season as well as for children at increased risk for severe RSV disease through their second RSV season. RSV season is the time of year when RSV infections are most common, usually occurring autumn through spring of the next year in temperate climates. Timing and severity in a given community or region can vary year to year.
About ENFLONSIA® (clesrovimab-cfor) in the U.S.
ENFLONSIA is Merck’s FDA-approved extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants who are born during or entering their first RSV season. ENFLONSIA is administered using the same dose regardless of weight (105 mg/0.7 mL in a prefilled syringe) and is designed to provide direct, rapid and durable protection through 5 months, a typical RSV season. For infants born during the RSV season, ENFLONSIA is to be administered within the first week of life. For infants born outside of the RSV season, ENFLONSIA should be administered shortly before the RSV season begins. For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose is recommended as soon as the infant is stable after surgery. ENFLONSIA has a 30-month shelf life.
Selected Safety Information for ENFLONSIA® (clesrovimab-cfor) in the U.S.
Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA.
Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
ENFLONSIA may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies. Confirmation using a reverse transcriptase polymerase chain reaction (RT-PCR) assay is recommended when rapid antigen assay results are negative and clinical observations are consistent with RSV infection.
The most common adverse reactions were injection-site erythema (4.5%), injection-site swelling (3.2%) and rash (2.3%).
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Please see Prescribing Information for ENFLONSIA (clesrovimab-cfor) at https://www.merck.com/product/usa/pi_circulars/e/enflonsia/enflonsia_pi.pdf and Patient Information/Medication Guide for ENFLONSIA at https://www.merck.com/product/usa/pi_circulars/e/enflonsia/enflonsia_ppi.pdf.
Contacts
Media Contacts:
Olivia Finucane
+44 7881 262476
Ilana Levine
(908) 421-1325
Investor Contacts:
Hayley Kasko
(732) 594-4237
Peter Dannenbaum
(732) 594-1579
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Opinion granted based on positive progression-free survival results from the Phase 3 LITESPARK-011 trial
If approved, this regimen will be the first and only approved combination of a HIF-2α inhibitor and a multi-targeted VEGFR-TKI in the European Union
RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway. A final decision is expected in the next two months.
“Patients with advanced renal cell carcinoma in the European Union have limited treatment options if their disease progresses following anti-PD-1 or anti-PD-L1 therapy,” said Dr. Christina Derleth, vice president, global oncology clinical development, Merck Research Laboratories. “This positive opinion is a meaningful step toward potentially bringing this first-of-its-kind regimen to patients in need in the European Union and underscores the important role of WELIREG plus lenvatinib as a new option in the treatment of renal cell carcinoma.”
The recommendation is based on results from the Phase 3 LITESPARK-011 trial. In the study, WELIREG in combination with lenvatinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the study’s dual primary endpoints, reducing the risk of disease progression or death by 26% (HR=0.74 [95% CI, 0.61-0.89]; p=0.001) in patients with advanced ccRCC whose disease progressed on or after treatment with a PD-1 or PD-L1 inhibitor compared to cabozantinib. Initial results for the trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. At the final analysis, overall survival (OS), the study’s other dual primary endpoint, did not meet statistical significance for patients who received WELIREG in combination with lenvatinib compared to cabozantinib. WELIREG in combination with lenvatinib reduced the risk of death by 15% (HR=0.85 [95% CI, 0.70-1.03]) in these patients compared to cabozantinib. Additionally, at the final analysis, the combination showed a continued benefit in objective response rate (ORR), a key secondary endpoint, of 53.1% for WELIREG plus lenvatinib versus 40.2% for cabozantinib. Similarly, WELIREG in combination with lenvatinib improved duration of response (DOR), another secondary endpoint, compared to cabozantinib, with a median DOR of 22.0 months versus 11.9 months, respectively. These results were presented at the European Society for Medical Oncology (ESMO) Congress 2026.
In September 2026, WELIREG in combination with LENVIMA® (lenvatinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced ccRCC following a PD-1 or PD-L1 inhibitor, based on results from the Phase 3 LITESPARK-011 trial.
About LITESPARK-011
LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced ccRCC. Eligible patients include participants with locally advanced or metastatic ccRCC who have progressed on or after a PD-1 or PD-L1 inhibitor, or within 6 months of completing adjuvant therapy with a PD-1 inhibitor. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily). The major efficacy endpoints were PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR) and OS. Objective response rate per RECIST v1.1 as assessed by BICR, DOR per RECIST v1.1 as assessed by BICR and safety were additional endpoints.
About renal cell carcinoma
Renal cell carcinoma is the most common type of kidney cancer, with about nine out of 10 kidney cancer diagnoses being RCC. In 2024, there were an estimated 442,570 new cases of kidney cancer and 144,871 deaths from the disease worldwide. Renal cell carcinoma is about twice as common in men as in women. Cases of RCC might be discovered incidentally during imaging tests for other reasons. Approximately 32% of patients with kidney cancer are diagnosed at a regional or metastatic stage. Clear cell renal cell carcinoma, which accounts for about 70% of RCC diagnoses, is the most common subtype.
About Merck’s research in genitourinary cancers
Merck is advancing research aimed at helping transform the treatment landscape and broaden options for people with genitourinary (GU) cancers, including bladder, kidney and prostate cancers. Globally, GU cancers account for an estimated 2.6 million new cancer diagnoses each year, equaling over 1 in 8 of all cancer incidences. Through a robust clinical development program with more than 50 ongoing clinical trials evaluating more than 22,000 patients around the world, Merck is investigating the potential of several portfolio medicines and pipeline assets, leveraging multiple novel combination strategies, across various stages of disease, to help address unmet needs in GU cancers.
About WELIREG® (belzutifan) 40 mg tablets, for oral use
WELIREG, Merck’s first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule that in conditions of hypoxia or impairment of VHL protein function, blocks HIF-2alpha and HIF-1beta interaction, which may reduce the transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG may disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival.
WELIREG has received regulatory approvals in certain patients with advanced renal cell carcinoma with a clear cell component (ccRCC) and adjuvant ccRCC in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, von Hippel-Lindau (VHL) disease-associated tumors and pheochromocytoma or paraganglioma (PPGL). As part of a broader clinical program, Merck continues to research WELIREG for people with RCC and selected solid tumors across different treatment settings, to further understand where WELIREG may provide clinical benefit.
Indications in the U.S.
von Hippel-Lindau disease
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Renal Cell Carcinoma with a Clear Cell Component
WELIREG, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the adjuvant treatment of adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
WELIREG, in combination with LENVIMA, is indicated for the treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
WELIREG, as monotherapy, is indicated for the treatment of adult patients with advanced ccRCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Pheochromocytoma or Paraganglioma
WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
Selected Safety Information for WELIREG
Warning: Embryo-Fetal Toxicity
Exposure to WELIREG during pregnancy can cause embryo-fetal harm. Verify pregnancy status prior to the initiation of WELIREG. Advise patients of these risks and the need for effective non-hormonal contraception as WELIREG can render some hormonal contraceptives ineffective.
Anemia
WELIREG can cause severe anemia that can require blood transfusion.
Monitor for anemia before initiation of, and periodically throughout, treatment with WELIREG. Transfuse patients as clinically indicated. Withhold, reduce dose, or permanently discontinue WELIREG based on severity.
In LITESPARK-004 (N=61), decreased hemoglobin occurred in 93% of patients with VHL disease and 7% had Grade 3 events. Median time to onset of anemia was 31 days (range: 1 day to 8.4 months).
The safety of erythropoiesis-stimulating agents (ESAs) for treatment of anemia in patients with VHL disease treated with WELIREG has not been established.
In LITESPARK-005, in patients receiving WELIREG for advanced ccRCC (n=372), decreased hemoglobin occurred in 88% of patients with advanced ccRCC and 29% had Grade 3 events. Median time to onset of anemia was 29 days (range: 1 day to 16.6 months). Of the patients with anemia, 22% received transfusions only, 20% received ESAs only, and 12% received both transfusion and ESAs.
In LITESPARK-022, in patients receiving WELIREG in combination with KEYTRUDA for adjuvant treatment for ccRCC (n=915), decreased hemoglobin occurred in 95% of patients and 11% had Grade 3 or higher events. Median time to onset of anemia was 42 days (range: 1 day to 11.1 months). Of the patients with anemia, 5% received transfusions only, 8% received erythropoiesis-stimulating agents (ESAs) only, and 1.3% received both transfusion and ESAs.
In LITESPARK-011, in patients receiving WELIREG in combination with LENVIMA for advanced ccRCC (n=370), decreased hemoglobin occurred in 87% of patients and 20% had Grade 3 events or required transfusion. Median time to onset of anemia was 56 days (range: 1 day to 33 months). Of the patients with anemia, 15% received transfusions only, 22% received erythropoiesis-stimulating agents (ESAs) only, and 8% received both transfusion and ESAs.
In LITESPARK-015 (n=72), anemia occurred in 96% of patients with PPGL and 22% had Grade 3 events. Median time to onset of anemia was 29 days (range: 1 day to 22.1 months). Of the patients with anemia, 20% received transfusions only, 26% received ESAs only, and 6% received both transfusion and ESAs.
Hypoxia
WELIREG can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization.
Monitor oxygen saturation before initiation of, and periodically throughout, treatment with WELIREG. For decreased oxygen saturation with exercise (e.g., pulse oximeter <88% or PaO2 ≤55 mm Hg), consider withholding WELIREG until pulse oximetry with exercise is greater than 88%, then resume at the same or a reduced dose. For decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO2 ≤55 mm Hg) or when urgent intervention is indicated, withhold WELIREG until resolved and resume at a reduced dose or discontinue. For life-threatening or recurrent symptomatic hypoxia, permanently discontinue WELIREG. Advise patients to report signs and symptoms of hypoxia immediately to a health care provider.
In LITESPARK-004, hypoxia occurred in 1.6% of patients with VHL disease.
In LITESPARK-005, in patients receiving WELIREG for advanced ccRCC, hypoxia occurred in 15% of patients with advanced ccRCC and 10% had Grade 3 events. Of the patients with hypoxia, 69% were treated with oxygen therapy. Median time to onset of hypoxia was 30.5 days (range: 1 day to 21.1 months).
In LITESPARK-022, in patients receiving WELIREG in combination with KEYTRUDA for adjuvant treatment for ccRCC, hypoxia occurred in 7% of patients receiving adjuvant treatment for ccRCC and 5% had Grade 3 or higher events. Of the patients with hypoxia, 47% were treated with oxygen therapy. Median time to onset of hypoxia was 93 days (range: 9 days to 11.7 months).
In LITESPARK-011, in patients receiving WELIREG in combination with LENVIMA for advanced ccRCC, hypoxia occurred in 16% of patients and 12% had Grade 3-4 events. Of the patients with hypoxia, 62% were treated with oxygen therapy. Median time to onset of hypoxia was 63 days (range: 4 days to 25 months).
In LITESPARK-015, hypoxia occurred in 13% of patients with PPGL and 10% had Grade 3 hypoxia. Median time to onset of hypoxia was 35 days (range: 6 days to 23.9 months). Of the patients with hypoxia, 67% were treated with oxygen therapy.
Cardiac Dysfunction with Concomitant Use of WELIREG and LENVIMA
Serious cardiac dysfunction, including heart failure with reduced left ventricular ejection fraction (LVEF), and cardiomyopathy, can occur with WELIREG in combination with LENVIMA. The safety of WELIREG in combination with LENVIMA has not been established in patients with LVEF below 50%.
In patients treated with WELIREG in combination with LENVIMA in the LITESPARK-011 trial, Grade 3 or higher cardiac dysfunction adverse events occurred in 6% of patients. The median time to onset of Grade 3 or higher of cardiac dysfunction was 26 weeks (range: 1 to 192 weeks). An absolute decrease in LVEF >20% with or without clinical symptoms occurred in 6% of patients. The median time to onset of LVEF decrease >20% was 29 weeks (range: 2 to 192 weeks).
Consider obtaining a baseline echocardiogram or Multigated Acquisition (MUGA) imaging. Monitor patients for symptoms or signs of heart failure and if present, reassess LVEF. Withhold and resume at a reduced dose upon recovery to baseline or Grade 1 or permanently discontinue WELIREG in combination with LENVIMA based on severity.
Embryo-Fetal Toxicity
Based on findings in animals, WELIREG can cause fetal harm when administered to a pregnant woman.
Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose. WELIREG can render some hormonal contraceptives ineffective. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose.
Adverse Reactions
Adverse Reactions in LITESPARK-004 (VHL disease)
Serious adverse reactions occurred in 15% of patients, including anemia, hypoxia, anaphylaxis reaction, retinal detachment, and central retinal vein occlusion (1 patient each).
WELIREG was permanently discontinued due to adverse reactions in 3.3% of patients for dizziness and opioid overdose (1.6% each).
Dosage interruptions due to an adverse reaction occurred in 39% of patients. Those which required dosage interruption in >2% of patients were fatigue, decreased hemoglobin, anemia, nausea, abdominal pain, headache, and influenza-like illness.
Dose reductions due to an adverse reaction occurred in 13% of patients. The most frequently reported adverse reaction which required dose reduction was fatigue (7%).
The most common adverse reactions (≥25%), including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin (93%), fatigue (64%), increased creatinine (64%), headache (39%), dizziness (38%), increased glucose (34%), and nausea (31%).
Adverse Reactions in LITESPARK-022 (Adjuvant ccRCC)
Serious adverse reactions occurred in 30% of patients receiving WELIREG in combination with KEYTRUDA. The most frequently reported serious adverse reactions (≥1%) were pneumonia (2%), hypoxia (1.9%), pneumonitis (1.6%), arrhythmia (1.5%), diarrhea (1.1%), and acute kidney injury (1.1%). Fatal adverse reactions occurred in 1.1% of patients who received WELIREG in combination with KEYTRUDA, including sepsis (0.1%).
WELIREG was permanently discontinued due to adverse reactions in 27% of patients. Adverse reactions which resulted in permanent discontinuation of WELIREG in ≥1% of patients included anemia (4%), fatigue (2.2%), rash (2%), increased alanine aminotransferase (ALT) (1.7%), hypoxia (1.6%), diarrhea (1.4%), pneumonitis (1.3%), increased aspartate aminotransferase (AST) (1.1%), and hepatic function abnormal (1%).
Dosage interruptions of WELIREG due to an adverse reaction occurred in 52% of patients. Of the patients who received WELIREG in combination with KEYTRUDA, 30% were ≥65 years old and 5% were ≥75 years old. Dose interruptions of WELIREG occurred in 57% of patients ≥65 years of age and in 49% of younger patients. Adverse reactions which required dosage interruption of WELIREG in ≥2% of patients included anemia (25%), fatigue (3.7%), increased ALT (3.5%), diarrhea (3.4%), increased AST (3.4%), COVID-19 (2.6%), hypoxia (2.5%), pyrexia (2.5%), musculoskeletal pain (2.1%), and rash (2.1%).
Dose reductions of WELIREG due to an adverse reaction occurred in 34% of patients. Dose reductions of WELIREG occurred in 39% of patients ≥65 years of age and in 32% of younger patients. Adverse reactions which required dose reduction in ≥3% of patients included anemia (17%), hypoxia (3.5%), increased ALT (3.2%), and fatigue (3.1%).
The most common (≥25%) adverse reactions, including laboratory abnormalities, in patients who received WELIREG in combination with KEYTRUDA were decreased hemoglobin (95%), increased ALT (57%), fatigue (49%), increased AST (46%), decreased lymphocytes (38%), and increased alkaline phosphatase (29%).
Adverse Reactions in LITESPARK-011 (Advanced ccRCC)
Serious adverse reactions occurred in 54% of patients who received WELIREG in combination with LENVIMA. Serious adverse reactions in ≥2% of patients included hypoxia (6%), pneumonia (5.0%), hyponatremia (3.2%), acute kidney injury (3%), hemorrhage (2.7%), anemia (2.7%), cardiac failure (2.4%), and diarrhea (2.4%). Fatal adverse reactions occurred in 5% of patients who received WELIREG in combination with LENVIMA, including sepsis (0.8%), pneumonia (0.5%), pneumonitis (0.5%), respiratory failure (0.5%), and one case (0.3%) each of acute cholecystitis, acute respiratory distress syndrome, pulmonary edema, embolic cerebral infarction, hemorrhage, postoperative wound complication, thrombotic microangiopathy, and upper respiratory tract infection.
Permanent discontinuation of WELIREG due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of WELIREG in >0.5% of patients included hypoxia (2.2%), pneumonia (1.1%), fatigue (0.8%), hyponatremia (0.8%), pneumonitis (0.8%), and respiratory failure (0.8%).
Dosage interruptions of WELIREG due to an adverse reaction occurred in 69% of patients. Adverse reactions which required dosage interruption in >3% of patients included fatigue (14%), diarrhea (12%), anemia (9%), vomiting (9%), hypertension (9%), nausea (8%), decreased appetite (5%), abdominal pain (4.6%), COVID-19 (4.6%), musculoskeletal pain (4.1%), pneumonia (3.5%), hypoxia (3.5%), and hemorrhage (3.5%).
Dose reductions of WELIREG due to an adverse reaction occurred in 35% of patients. Adverse reactions which required dose reductions in >2% of patients included fatigue (7%), hypoxia (7%), anemia (6%), diarrhea (3%), and dyspnea (2.4%).
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG in combination with LENVIMA were decreased hemoglobin, fatigue, increased AST, hypertension, increased ALT, musculoskeletal pain, diarrhea, decreased lymphocytes, decreased sodium, increased creatinine, nausea, hypothyroidism, decreased appetite, decreased platelets, increased potassium, increased lipase, proteinuria, decreased magnesium, decreased calcium, increased activated partial thromboplastin time, rash, vomiting, decreased weight, constipation, abdominal pain, and stomatitis.
Adverse Reactions in LITESPARK-005 (Advanced ccRCC)
Serious adverse reactions occurred in 38% of patients. The most frequently reported serious adverse reactions (≥2%) were hypoxia (7%), anemia (5%), pneumonia (3.5%), hemorrhage (3%), and pleural effusion (2.2%). Fatal adverse reactions occurred in 3.2% of patients who received WELIREG, including sepsis (0.5%) and hemorrhage (0.5%).
WELIREG was permanently discontinued due to adverse reactions in 6% of patients. Adverse reactions which resulted in permanent discontinuation (≥0.5%) were hypoxia (1.1%), anemia (0.5%), and hemorrhage (0.5%).
Dosage interruptions due to an adverse reaction occurred in 39% of patients. Of the patients who received WELIREG, 28% were 65 to 74 years, and 10% were 75 years and over. Dose interruptions occurred in 48% of patients ≥65 years of age and in 34% of younger patients. Adverse reactions which required dosage interruption in ≥2% of patients were anemia (8%), hypoxia (5%), COVID-19 (4.3%), fatigue (3.2%), and hemorrhage (2.2%).
Dose reductions due to an adverse reaction occurred in 13% of patients. Dose reductions occurred in 18% of patients ≥65 years of age and in 10% of younger patients. The most frequently reported adverse reactions which required dose reduction (≥1%) were hypoxia (5%) and anemia (3.2%).
The most common adverse reactions (≥25%), including laboratory abnormalities, were decreased hemoglobin (88%), fatigue (43%), musculoskeletal pain (34%), increased creatinine (34%), decreased lymphocytes (34%), increased alanine aminotransferase (32%), decreased sodium (31%), increased potassium (29%), and increased aspartate aminotransferase (27%).
Adverse Reactions in LITESPARK-015 (PPGL)
Serious adverse reactions occurred in 36% of patients. The most frequently reported serious adverse reactions (≥2%) were anemia and hypertension (4.2% each) and pyelonephritis, pneumonia, hypoxia, dyspnea and hemorrhage (2.8% each).
WELIREG was permanently discontinued due to adverse reactions in 2 patients (2.8%). Adverse reactions which resulted in permanent discontinuation were increased alanine aminotransferase and paraparesis (1.4% each).
Dosage interruptions due to an adverse reaction occurred in 40% of patients. Of the patients who received WELIREG, 13% were ≥65 years old and 4.2% were ≥75 years. Adverse reactions which required dosage interruption in >3% of patients were hypoxia, nausea, and fatigue (4.2% each).
Dose reductions due to an adverse reaction occurred in 14% of patients. The most frequently reported adverse reaction which required dose reduction was hypoxia (4.2%).
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients were anemia (96%), fatigue (56%), musculoskeletal pain (56%), decreased lymphocytes (54%), increased alanine aminotransferase (51%), increased aspartate aminotransferase (42%), increased calcium (34%), dyspnea (33%), increased potassium (31%), decreased leukocytes (30%), headache (29%), increased alkaline phosphatase (25%), dizziness (26%) and nausea (25%).
Contacts
Media Contacts:
Julie Cunningham
julie.cunningham@merck.com
AJ Seymour
andrew.seymour@merck.com
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement
IRVINE, Calif.–(BUSINESS WIRE)–$SBC #Healthcare–SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026).
Third Quarter 2026 Financial Highlights
- Total revenues were $59 million, up 35% year-over-year.
- Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%.
- Net income attributable to SBC Medical was $16 million, up 22% year-over-year. Net income margin was 27%, a decrease of 3 percentage points year-over-year.
- Adjusted EBITDA1 was $28 million, up 66% year-over-year. Adjusted EBITDA margin1 expanded 9 percentage points year-over-year to 47%.
- Basic earnings per share (EPS) was $0.15, up 25% year-over-year.
- Net cash provided by operating activities totaled $50 million for the nine months ended September 30, 2026.
Third-quarter results reflected both growth and improved profitability in the core MSO business. Revenue growth was driven by higher management services revenue, including the impact of service fee structure revisions announced in August, as well as the consolidation of Waqoo.
The medical corporations supported by SBC Medical continued to expand. As of September 30, 2026, the clinic network had increased by 36 locations year-over-year to 293 locations2. Patient visits3 over the trailing twelve months totaled 7.06 million, up 9% year-over-year. Average spend per visit was $290, up 4% year-over-year.
Comment from SBC Medical’s Chairman and CEO Yoshiyuki Aikawa:
“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA1 margin of 47%. Following the structural reforms implemented in 2025, growth and profitability are improving in tandem, demonstrating the strength of our highly profitable MSO model.
Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently. This quarter’s growth in management services revenue, including the effect of service fee revisions, demonstrates progress in this model.
To strengthen this model further, we are investing in AI and technology. Specifically, we are developing a proprietary local large language model (LLM) infrastructure designed to enable the secure use of medical data while optimizing AI costs, while also advancing our clinic operating systems through our capital and business alliance with Atomic Software. Together, these initiatives are intended to improve profitability at existing clinics and make new clinic openings more efficient, enabling our scalable MSO platform to generate greater earnings power as the business expands.
Our Longevity business, which we view as our next growth opportunity, is also making tangible progress. As a first step, we are developing an in-house DNA methylation-based test to estimate biological age, drawing on the Waqoo Group’s research and technology capabilities. By adding diagnostics to our existing medical network and combining AI with physicians’ expertise, we aim to build an integrated platform spanning testing, personalized treatment and evaluation of outcomes.
In Japan, we will continue expanding our multi-brand presence in aesthetic dermatology and broadening our non-aesthetic medical services. Internationally, we are pursuing collaboration with OrangeTwist in the United States and expansion across ASEAN markets. These initiatives are designed to unlock further growth in our existing business while pursuing opportunities in new markets.
For the first nine months of 2026, net cash provided by operating activities totaled $50 million. As of September 30, 2026, we held $198 million in cash and cash equivalents and $154 million in Net Cash4. We intend to deploy this strong financial position toward disciplined growth investment, with the goal of sustaining EPS growth over the medium- to long-term and enhancing corporate value.”
Summary of Key Financials
|
|
Unit |
3Q26 |
3Q25 |
YoY |
9M26 |
9M25 |
YoY |
|
Total Revenues |
$MM |
59 |
43 |
+35% |
151 |
134 |
+13% |
|
Net Income Attributable to |
$MM |
16 |
13 |
+22% |
38 |
37 |
+2% |
|
Net Income Margin |
% |
27 |
30 |
(3)pt |
25 |
27 |
(2)pt |
|
Adjusted EBITDA 1 |
$MM |
28 |
17 |
+66% |
66 |
57 |
+17% |
|
Adjusted EBITDA Margin 1 |
% |
47 |
38 |
+9pt |
44 |
42 |
+2pt |
|
ROE (Annualized) 5 |
% |
23 |
23 |
(0)pt |
19 |
22 |
(3)pt |
|
Basic EPS 6 |
$ |
0.15 |
0.12 |
+25% |
0.37 |
0.36 |
+3% |
1 Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please refer to “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Measures (unaudited).”
2 Represents the total number of locations across the Company’s support and partnership network, including franchised locations of SBC-branded clinics, Rize Clinic, Gorilla Clinic, AHH Clinic and JUN CLINIC, as well as locations operated by OrangeTwist, in which the Company holds a minority equity interest through its equity method investment in OT Midco Holdings, LLC.
3 Patient visits include patients of SBC-branded clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN CLINIC. The period covered is from October 1, 2025 to September 30, 2026.
4 Net Cash is a non-GAAP financial measure, calculated as cash and cash equivalents ($198 million), less bank and other borrowings and finance lease liabilities, current and non-current ($34 million), and operating lease liabilities, current and non-current ($10 million), each as presented in the unaudited consolidated balance sheet as of September 30, 2026, resulting in Net Cash of $154 million.
5 Return on equity (ROE) is calculated as net income attributable to SBC Medical divided by average shareholders’ equity (beginning and end of period).
6 Basic EPS is calculated as net income attributable to SBC Medical divided by the weighted average number of shares outstanding.
Conference Call
The Company will hold a conference call on Friday, November 13th, 2026 at 08:30 a.m. Eastern Time (or Friday, November 13th, 2026 at 10:30 p.m. Japan Time) to discuss the financial results for the third quarter ended September 30, 2026. A question-and-answer session will follow the prepared remarks.
During the live webcast, participants may submit questions in real-time using the Zoom Q&A button.
All attendees, regardless of their current stock ownership status, are welcome to submit questions. Please note that due to time constraints and the nature of the inquiries, we may not be able to address every question during the call.
Please register in advance of the conference using the link provided below:
https://zoom.us/webinar/register/WN_CLFqOL3XTourhX2qjAJnxw#/registration
Upon registration, you will be able to access the dedicated conference call viewing site.
Additionally, the earnings release, accompanying slides, and a separate link to the archived webcast of this conference call will be available on the Company’s Investor Relations website at https://ir.sbc-holdings.com/.
About SBC Medical
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
Company Name: SBC Medical Group Holdings Incorporated | Listed Market: NASDAQ Global Market | Ticker: SBC | Address: 200 Spectrum Center Drive, Suite 300, Irvine, CA 92618 USA | IR Website: https://ir.sbc-holdings.com/ | LinkedIn: https://www.linkedin.com/company/sbc-medical-group-holdings-inc
Use of Non-GAAP Financial Measures
The Company uses non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA margin and Net Cash, in evaluating its operating results and financial position and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business, provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects, and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making. In particular, the Company believes Net Cash is useful to investors in evaluating the Company’s liquidity and financial position, including its capacity to fund growth investments.
The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. For reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures, see the reconciliations included at the end of this press release and, for Net Cash, footnote 4 to the “Summary of Key Financials.”
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
|
SBC MEDICAL GROUP HOLDINGS INCORPORATED |
||||||||
|
|
|
September 30, |
|
|
December 31, |
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
198,428,275 |
|
|
$ |
163,773,838 |
|
|
Time deposits |
|
|
4,000,000 |
|
|
|
— |
|
|
Accounts receivable |
|
|
2,540,219 |
|
|
|
2,388,021 |
|
|
Accounts receivable – related parties |
|
|
30,931,517 |
|
|
|
27,511,730 |
|
|
Inventories |
|
|
2,949,218 |
|
|
|
2,792,617 |
|
|
Short-term investments – related parties |
|
|
318,297 |
|
|
|
319,193 |
|
|
Finance lease receivables, current – related parties |
|
|
16,143,695 |
|
|
|
12,832,355 |
|
|
Income tax recoverable |
|
|
1,292,660 |
|
|
|
1,175,510 |
|
|
Customer loans receivable, current |
|
|
3,966,531 |
|
|
|
8,705,999 |
|
|
Prepaid expenses and other current assets |
|
|
10,762,659 |
|
|
|
11,724,852 |
|
|
Prepaid expenses and other receivables – related parties |
|
|
2,522,970 |
|
|
|
— |
|
|
Total current assets |
|
|
273,856,041 |
|
|
|
231,224,115 |
|
|
|
|
|
|
|
|
|
||
|
Non-current assets: |
|
|
|
|
|
|
||
|
Property and equipment, net |
|
|
8,527,530 |
|
|
|
7,539,392 |
|
|
Intangible assets, net |
|
|
45,226,994 |
|
|
|
47,742,888 |
|
|
Long-term investments, net |
|
|
1,880,112 |
|
|
|
1,299,366 |
|
|
Equity method investments |
|
|
19,157,291 |
|
|
|
20,312,642 |
|
|
Goodwill, net |
|
|
15,075,256 |
|
|
|
15,432,061 |
|
|
Finance lease receivables, non-current – related parties |
|
|
14,448,126 |
|
|
|
13,746,513 |
|
|
Operating lease right-of-use assets |
|
|
10,150,912 |
|
|
|
8,366,569 |
|
|
Finance lease right-of-use assets |
|
|
277,827 |
|
|
|
450,874 |
|
|
Deferred tax assets |
|
|
8,000,383 |
|
|
|
4,014,294 |
|
|
Customer loans receivable, non-current |
|
|
2,325,289 |
|
|
|
4,824,977 |
|
|
Long-term prepayments |
|
|
522,473 |
|
|
|
393,270 |
|
|
Long-term investments in MCs – related parties |
|
|
17,787,217 |
|
|
|
17,837,293 |
|
|
Other assets |
|
|
7,587,608 |
|
|
|
7,263,692 |
|
|
Total non-current assets |
|
|
150,967,018 |
|
|
|
149,223,831 |
|
|
Total assets |
|
$ |
424,823,059 |
|
|
$ |
380,447,946 |
|
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
23,408,185 |
|
|
$ |
16,988,384 |
|
|
Accounts payable – related parties |
|
|
918,135 |
|
|
|
651,463 |
|
|
Bank and other borrowings, current |
|
|
8,757,956 |
|
|
|
9,099,046 |
|
|
Advances from customers |
|
|
877,664 |
|
|
|
1,415,762 |
|
|
Advances from customers – related parties |
|
|
3,600,523 |
|
|
|
5,357,221 |
|
|
Income tax payable |
|
|
16,707,822 |
|
|
|
8,821,853 |
|
|
Operating lease liabilities, current |
|
|
5,754,161 |
|
|
|
4,416,960 |
|
|
Finance lease liabilities, current |
|
|
88,091 |
|
|
|
132,946 |
|
|
Accrued liabilities and other current liabilities |
|
|
14,552,613 |
|
|
|
11,544,695 |
|
|
Due to related party |
|
|
— |
|
|
|
2,692,673 |
|
|
Total current liabilities |
|
|
74,665,150 |
|
|
|
61,121,003 |
|
|
|
|
|
|
|
|
|
||
|
Non-current liabilities: |
|
|
|
|
|
|
||
|
Bank and other borrowings, non-current |
|
|
24,845,177 |
|
|
|
33,734,438 |
|
|
Deferred tax liabilities |
|
|
15,614,455 |
|
|
|
16,374,832 |
|
|
Operating lease liabilities, non-current |
|
|
4,541,685 |
|
|
|
4,136,257 |
|
|
Finance lease liabilities, non-current |
|
|
62,857 |
|
|
|
116,527 |
|
|
Other liabilities |
|
|
1,620,786 |
|
|
|
1,660,183 |
|
|
Total non-current liabilities |
|
|
46,684,960 |
|
|
|
56,022,237 |
|
|
Total liabilities |
|
|
121,350,110 |
|
|
|
117,143,240 |
|
|
|
|
|
|
|
|
|
||
|
Stockholders’ equity: |
|
|
|
|
|
|
||
|
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025) |
|
|
— |
|
|
|
— |
|
|
Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 shares issued, and 102,576,943 shares outstanding as of September 30, 2026 and December 31, 2025) |
|
|
10,388 |
|
|
|
10,388 |
|
|
Additional paid-in capital |
|
|
75,660,743 |
|
|
|
72,867,424 |
|
|
Treasury stock (at cost, 1,304,308 shares as of September 30, 2026 and December 31, 2025) |
|
|
(7,749,997 |
) |
|
|
(7,749,997 |
) |
|
Retained earnings |
|
|
278,142,255 |
|
|
|
240,448,620 |
|
|
Accumulated other comprehensive loss |
|
|
(59,214,802 |
) |
|
|
(57,294,239 |
) |
|
Total SBC Medical Group Holdings Incorporated stockholders’ equity |
|
|
286,848,587 |
|
|
|
248,282,196 |
|
|
Non-controlling interests |
|
|
16,624,362 |
|
|
|
15,022,510 |
|
|
Total stockholders’ equity |
|
|
303,472,949 |
|
|
|
263,304,706 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
424,823,059 |
|
|
$ |
380,447,946 |
|
|
SBC MEDICAL GROUP HOLDINGS INCORPORATED |
||||||||||||||||
|
|
|
For the Three Months |
|
|
For the Nine Months |
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
Revenues, net – related parties |
|
$ |
53,518,360 |
|
|
$ |
39,617,548 |
|
|
$ |
135,205,614 |
|
|
$ |
123,819,591 |
|
|
Revenues, net |
|
|
5,063,160 |
|
|
|
3,735,687 |
|
|
|
15,624,536 |
|
|
|
10,221,192 |
|
|
Total revenues, net |
|
|
58,581,520 |
|
|
|
43,353,235 |
|
|
|
150,830,150 |
|
|
|
134,040,783 |
|
|
Cost of revenues (including cost of revenues from related parties of $1,749,587 and $4,018,377 for the three months ended September 30, 2026 and 2025, and $2,012,569 and $12,144,907 for the nine months ended September 30, 2026 and 2025, respectively) |
|
|
16,402,500 |
|
|
|
12,741,748 |
|
|
|
42,327,080 |
|
|
|
35,685,635 |
|
|
Gross profit |
|
|
42,179,020 |
|
|
|
30,611,487 |
|
|
|
108,503,070 |
|
|
|
98,355,148 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $877,328 and $154,063 for the three months ended September 30, 2026 and 2025, and $1,562,231 and $569,830 for the nine months ended September 30, 2026 and 2025, respectively) |
|
|
15,761,753 |
|
|
|
14,730,247 |
|
|
|
45,405,238 |
|
|
|
43,717,642 |
|
|
Total operating expenses |
|
|
15,761,753 |
|
|
|
14,730,247 |
|
|
|
45,405,238 |
|
|
|
43,717,642 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income from operations |
|
|
26,417,267 |
|
|
|
15,881,240 |
|
|
|
63,097,832 |
|
|
|
54,637,506 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Other income (expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest income (including interest income from related parties of $1,582 and nil for the three months ended September 30, 2026 and 2025, and $5,047 and nil for the nine months ended September 30, 2026 and 2025, respectively) |
|
|
344,937 |
|
|
|
120,384 |
|
|
|
474,826 |
|
|
|
198,599 |
|
|
Interest expense |
|
|
(128,878 |
) |
|
|
(48,635 |
) |
|
|
(372,313 |
) |
|
|
(104,493 |
) |
|
Foreign currency exchange gain (loss), net |
|
|
(947,087 |
) |
|
|
923,671 |
|
|
|
946,850 |
|
|
|
(904,575 |
) |
|
Other income (including other income from related parties of nil and $3,069 for the three months ended September 30, 2026 and 2025, and nil and $3,069 for the nine months ended September 30, 2026 and 2025, respectively) |
|
|
695,294 |
|
|
|
1,632,527 |
|
|
|
1,323,914 |
|
|
|
1,929,258 |
|
|
Other expenses |
|
|
— |
|
|
|
(2,323 |
) |
|
|
(678,279 |
) |
|
|
(1,003,801 |
) |
|
Gain on redemption of life insurance policies |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,746,138 |
|
|
Total other income (expenses) |
|
|
(35,734 |
) |
|
|
2,625,624 |
|
|
|
1,694,998 |
|
|
|
8,861,126 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income before income taxes and equity in losses of equity method investees |
|
|
26,381,533 |
|
|
|
18,506,864 |
|
|
|
64,792,830 |
|
|
|
63,498,632 |
|
|
Income tax expense |
|
|
(9,378,075 |
) |
|
|
(5,673,538 |
) |
|
|
(24,729,409 |
) |
|
|
(26,733,504 |
) |
|
Equity in losses of equity method investees, net of tax |
|
|
(586,699 |
) |
|
|
— |
|
|
|
(1,155,351 |
) |
|
|
— |
|
|
Net income |
|
|
16,416,759 |
|
|
|
12,833,326 |
|
|
|
38,908,070 |
|
|
|
36,765,128 |
|
|
Less: net income (loss) attributable to non-controlling interests |
|
|
724,017 |
|
|
|
8,690 |
|
|
|
1,214,435 |
|
|
|
(20,194 |
) |
|
Net income attributable to SBC Medical Group Holdings Incorporated |
|
$ |
15,692,742 |
|
|
$ |
12,824,636 |
|
|
$ |
37,693,635 |
|
|
$ |
36,785,322 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Foreign currency translation adjustment |
|
$ |
7,066,384 |
|
|
$ |
(6,791,961 |
) |
|
$ |
(2,502,636 |
) |
|
$ |
11,639,635 |
|
|
Total comprehensive income |
|
|
23,483,143 |
|
|
|
6,041,365 |
|
|
|
36,405,434 |
|
|
|
48,404,763 |
|
|
Less: comprehensive income attributable to non-controlling interests |
|
|
415,698 |
|
|
|
10,329 |
|
|
|
632,362 |
|
|
|
157,908 |
|
|
Comprehensive income attributable to SBC Medical Group Holdings Incorporated |
|
$ |
23,067,445 |
|
|
$ |
6,031,036 |
|
|
$ |
35,773,072 |
|
|
$ |
48,246,855 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income per share attributable to SBC Medical Group Holdings Incorporated |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic and diluted |
|
$ |
0.15 |
|
|
$ |
0.12 |
|
|
$ |
0.37 |
|
|
$ |
0.36 |
|
|
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic and diluted |
|
|
102,576,943 |
|
|
|
102,642,634 |
|
|
|
102,576,943 |
|
|
|
103,139,851 |
|
|
SBC MEDICAL GROUP HOLDINGS INCORPORATED |
||||||||
|
|
|
For the Nine Months |
|
|||||
|
|
|
2026 |
|
|
2025 |
|
||
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
||
|
Net income |
|
$ |
38,908,070 |
|
|
$ |
36,765,128 |
|
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
||
|
Depreciation and amortization expense |
|
|
2,979,917 |
|
|
|
2,010,616 |
|
|
Non-cash lease expense |
|
|
4,239,772 |
|
|
|
3,436,789 |
|
|
Provision for (reversal of) credit losses |
|
|
(22,236 |
) |
|
|
305,963 |
|
|
Equity in losses of equity method investees |
|
|
1,155,351 |
|
|
|
— |
|
|
Stock-based compensation |
|
|
19,541 |
|
|
|
— |
|
|
Fair value change of long-term investments |
|
|
(579,154 |
) |
|
|
(724,476 |
) |
|
Gain on redemption of life insurance policies |
|
|
— |
|
|
|
(8,746,138 |
) |
|
Loss (gain) on disposal of property and equipment |
|
|
9,375 |
|
|
|
(414,167 |
) |
|
Change in fair value of cryptocurrencies |
|
|
— |
|
|
|
(146,036 |
) |
|
Deferred income taxes |
|
|
(4,386,410 |
) |
|
|
9,104,235 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
|
Accounts receivable |
|
|
(197,484 |
) |
|
|
(1,084,316 |
) |
|
Accounts receivable – related parties |
|
|
(3,502,443 |
) |
|
|
(28,031,690 |
) |
|
Inventories |
|
|
(191,314 |
) |
|
|
265,052 |
|
|
Finance lease receivables – related parties |
|
|
(4,050,925 |
) |
|
|
(9,227,612 |
) |
|
Customer loans receivable |
|
|
7,158,848 |
|
|
|
12,153,263 |
|
|
Prepaid expenses and other current assets |
|
|
923,442 |
|
|
|
(2,180,695 |
) |
|
Prepaid expenses and other receivables – related parties |
|
|
(2,500,352 |
) |
|
|
— |
|
|
Long-term prepayments |
|
|
(375,662 |
) |
|
|
281,666 |
|
|
Other assets |
|
|
(390,302 |
) |
|
|
77,609 |
|
|
Accounts payable |
|
|
6,551,564 |
|
|
|
2,549,938 |
|
|
Accounts payable – related parties |
|
|
280,593 |
|
|
|
2,144,314 |
|
|
Notes payable – related parties |
|
|
— |
|
|
|
(12,759,536 |
) |
|
Advances from customers |
|
|
(528,982 |
) |
|
|
161,165 |
|
|
Advances from customers – related parties |
|
|
(1,726,044 |
) |
|
|
(5,470,844 |
) |
|
Income tax payable |
|
|
7,711,189 |
|
|
|
(19,936,155 |
) |
|
Operating lease liabilities |
|
|
(4,279,802 |
) |
|
|
(3,639,887 |
) |
|
Accrued liabilities and other current liabilities |
|
|
3,059,724 |
|
|
|
(4,096,471 |
) |
|
Other liabilities |
|
|
(18,888 |
) |
|
|
(93,141 |
) |
|
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES |
|
|
50,247,388 |
|
|
|
(27,295,426 |
) |
|
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
||
|
Purchase of property and equipment |
|
|
(1,214,421 |
) |
|
|
(603,484 |
) |
|
Prepayments for property and equipment |
|
|
(888,098 |
) |
|
|
(838,568 |
) |
|
Payments made on behalf of related parties |
|
|
— |
|
|
|
(1,840,801 |
) |
|
Purchase of long-term investments |
|
|
— |
|
|
|
(654,070 |
) |
|
Placement of time deposits |
|
|
(4,000,000 |
) |
|
|
— |
|
|
Purchase of cryptocurrencies |
|
|
— |
|
|
|
(424,250 |
) |
|
Cash paid for acquisition of subsidiaries, net of cash acquired |
|
|
— |
|
|
|
(14,861,858 |
) |
|
Long-term loans to others |
|
|
— |
|
|
|
(14,514 |
) |
|
Repayments from related parties |
|
|
— |
|
|
|
1,911,440 |
|
|
Repayments from others |
|
|
41,765 |
|
|
|
73,928 |
|
|
Proceeds from redemption of life insurance policies |
|
|
— |
|
|
|
17,735,717 |
|
|
Deconsolidation of VIE, net of cash disposed of |
|
|
1,019,909 |
|
|
|
— |
|
|
Proceeds from disposal of property and equipment |
|
|
— |
|
|
|
2,755,983 |
|
|
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES |
|
|
(5,040,845 |
) |
|
|
3,239,523 |
|
|
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
||
|
Borrowings from bank and others |
|
|
— |
|
|
|
14,851,980 |
|
|
Borrowings from related parties |
|
|
— |
|
|
|
15,000 |
|
|
Proceeds from exercise of stock acquisition rights in subsidiary by non-controlling interests |
|
|
94,843 |
|
|
|
— |
|
|
Repayments of bank and other borrowings |
|
|
(8,912,553 |
) |
|
|
(721,874 |
) |
|
Repayments of finance lease liabilities |
|
|
(99,932 |
) |
|
|
(310,603 |
) |
|
Repayments to related parties |
|
|
(22,657 |
) |
|
|
(46,782 |
) |
|
Repurchase of common stock |
|
|
— |
|
|
|
(4,999,997 |
) |
|
Deemed contribution in connection with price modification on disposal of property and equipment |
|
|
— |
|
|
|
9,682,277 |
|
|
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES |
|
|
(8,940,299 |
) |
|
|
18,470,001 |
|
|
|
|
|
|
|
|
|
||
|
Effect of exchange rate changes |
|
|
(1,611,807 |
) |
|
|
7,973,128 |
|
|
|
|
|
|
|
|
|
||
|
NET CHANGE IN CASH AND CASH EQUIVALENTS |
|
|
34,654,437 |
|
|
|
2,387,226 |
|
|
CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD |
|
|
163,773,838 |
|
|
|
125,044,092 |
|
|
CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD |
|
$ |
198,428,275 |
|
|
$ |
127,431,318 |
|
|
|
|
|
|
|
|
|
||
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
|
|
|
|
|
|
||
|
Cash paid for interest expense |
|
$ |
372,313 |
|
|
$ |
104,493 |
|
|
Cash paid for income taxes, net |
|
$ |
21,135,092 |
|
|
$ |
37,555,740 |
|
|
|
|
|
|
|
|
|
||
|
NON-CASH INVESTING AND FINANCING ACTIVITIES |
|
|
|
|
|
|
||
|
Property and equipment transferred from prepaid expenses |
|
$ |
57,013 |
|
|
$ |
— |
|
|
Property and equipment transferred from long-term prepayments |
|
$ |
1,050,946 |
|
|
$ |
1,428,254 |
|
|
Operating lease right-of-use assets obtained in exchange for operating lease liabilities |
|
$ |
221,443 |
|
|
$ |
105,556 |
|
|
Finance lease right-of-use assets obtained in exchange for finance lease liabilities |
|
$ |
— |
|
|
$ |
612,466 |
|
|
Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications |
|
$ |
5,845,817 |
|
|
$ |
2,646,028 |
|
|
Payables to related parties in connection with loan services provided |
|
$ |
— |
|
|
$ |
14,362,902 |
|
|
Issuance of common stock as incentive shares |
|
$ |
— |
|
|
$ |
86 |
|
Contacts
SBC Medical Group Holdings Incorporated — Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China
LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China
LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China
- Anzupgo® (delgocitinib) cream has been approved by China’s National Medical Products Administration (NMPA) for adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.
- The approval is supported by positive results from the DELTA China phase 3 trial, together with the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3 and DELTA Force.1-7
- The approval reflects LEO Pharma’s commitment to improving care for adults living with moderate to severe chronic hand eczema in China, an exciting and important market for the company.
BALLERUP, Denmark–(BUSINESS WIRE)–NOT FOR UK USE – NOT INTENDED FOR UK MEDIA
LEO Pharma A/S, a global leader in medical dermatology, today announced that China’s National Medical Products Administration (NMPA) has approved Anzupgo® (delgocitinib) cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.
The approval represents a significant step in expanding access to Anzupgo for patients in China and provides a new treatment option for adult patients living with moderate to severe CHE.
“The approval of Anzupgo in China is an important milestone for LEO Pharma and for patients living with moderate to severe chronic hand eczema,” said Frederik Kier, Executive Vice President, International Operations, LEO Pharma. “China is an important market for LEO Pharma, and this approval reflects our continued commitment to supporting skin health in China and bringing innovative treatment options to those who need them most.”
With the approval of Anzupgo in China, LEO Pharma strengthens its presence in a large, important and evolving healthcare market in terms of patient numbers, underlining the scale of patient need and providing a strong foundation for making this treatment option available to adults with moderate to severe disease.
Chronic hand eczema is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema and fissures on the hands and wrists.8
CHE can place a substantial psychological and functional burden on patients, affecting quality of life and daily functioning, with approximately 70% of individuals living with severe CHE reporting problems performing everyday activities and disruption in daily life due to the disease.9-11
“People living with chronic hand eczema can experience a significant burden in their daily lives, Currently, there are no treatments specifically indicated for chronic hand eczema in China, creating a clear need for new treatment options in China,” said Byron Yin, General Manager, LEO Pharma China. “The approval of Anzupgo is an important step forward for patients and healthcare professionals, and we are proud to bring this innovation to China as part of our ongoing commitment to improving care for people living with skin diseases.”
The approval is supported by DELTA China, a phase 3 trial evaluating the efficacy, safety and pharmacokinetics of twice-daily applications of Anzupgo in Chinese patients with moderate to severe CHE.1,2 In the double-blind treatment period of DELTA China, Anzupgo met the primary endpoint, showing a statistically significant improvement in CHE severity after 16 weeks of treatment compared with cream vehicle.1,2 The approval is also supported by the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3, DELTA Force.3-7
“The impact of chronic hand eczema goes beyond the skin. It can affect patients’ daily lives, careers and psychological well-being, yet these effects are often overlooked. Many patients face the burden of the disease on their own and continue searching for solutions as the disease flares repeatedly, said Professor Zhang Jianzhong of Peking University People’s Hospital, lead investigator of the DELTA China trial. “We hope to raise awareness of the challenges patients face and promote a better understanding of chronic hand eczema and its appropriate management. We are pleased that delgocitinib cream has now been approved, offering a new treatment option and additional possibilities for improving patients’ lives.”
About Chronic Hand Eczema
Chronic hand eczema (CHE) is defined as hand eczema that lasts for more than three months or relapses twice or more within a year.12,13 CHE is one of the most common skin diseases of the hands with a global prevalence rate of approximately 4.7%.14,15 In a substantial number of patients, hand eczema can develop into a chronic disease.14 CHE is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema and fissures on hands and wrists.8
CHE has been shown to cause psychological and functional burdens that impact patient quality of life.9,10 Approximately 70% of adults who live with severe CHE have reported problems in performing everyday activities and disruption in their daily life due to the condition.11 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.16
About Anzupgo® (delgocitinib) Cream
Anzupgo® cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE in adults and adolescents. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.17
Anzupgo® is approved in several markets, including the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea and the United Arab Emirates for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. In the European Union and the United Arab Emirates, Anzupgo® is furthermore approved for the treatment of moderate to severe chronic hand eczema in adolescents aged 12-17 for whom topical corticosteroids are inadequate or inappropriate. Anzupgo® cream is also being rolled out in other markets.
Anzupgo® (delgocitinib) cream is FDA approved in the U.S. for moderate to severe chronic hand eczema in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.18
In 2014, LEO Pharma obtained the exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where Shionogi & Co., Ltd. owns the rights.
About the DELTA China trial
DELTA China is a phase 3 trial to evaluate efficacy, safety and pharmacokinetics of twice-daily applications of Anzupgo in Chinese patients with moderate to severe CHE.2
The primary endpoint of the DELTA China trial was the Investigator’s Global Assessment for CHE treatment success (IGA-CHE TS) at Week 16.2
Treatment success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline.2
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,300 people worldwide. Together, we reach far beyond the skin.
For more information, visit www.leo-pharma.com.
References
- LEO Pharma Press Release. LEO Pharma Meets Primary Endpoint in Phase 3 DELTA China Trial with Anzupgo® (delgocitinib) Cream in Chinese Patients with Moderate to Severe Chronic Hand Eczema (CHE). Published: February 25, 2025. Last accessed: October, 2025. Available at: https://www.biospace.com/press-releases/leo-pharma-meets-primary-endpoint-in-phase-3-delta-china-trial-with-anzupgo-delgocitinib-cream-in-chinese-patients-with-moderate-to-severe-chronic-hand-eczema-che
- ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema. Identifier: NCT06004050. https://clinicaltrials.gov/study/NCT06004050.
- ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). Identifier: NCT04871711. https://clinicaltrials.gov/study/NCT04871711.
- ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2). Identifier: NCT04872101. https://clinicaltrials.gov/ct2/show/NCT04872101.
- Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461-473.
- ClinicalTrials.gov. National Library of Medicine (U.S.). Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA3). Identifier: NCT04949841. https://clinicaltrials.gov/ct2/show/NCT04949841.
- ClinicalTrials.gov. National Library of Medicine (U.S.). A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema. Iden-tifier: NCT05259722. https://clinicaltrials.gov/study/NCT05259722.
- Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378.
- Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.
- Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991.
- Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168.
- Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360.
- Diepgen TL, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1-22.
- Bissonnette R, et al. Redefining treatment options in chronic hand eczema (CHE). JEADV. 2010;24:1-20.
- Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3.
- Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626.
- Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.
- ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025.
Contacts
Christian Bundgaard
Global Corporate Communication
+45 53 74 88 49
chbun@leo-pharma.com
Jes Broe Frederiksen
Global Corporate Communication
+45 53 60 59 48
jebfe@leo-pharma.com
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication
- Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027
- Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1
- The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6
- The approval reinforces Galderma’s commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs
ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6
The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as aging can contribute to changes in fat layers, which can result in tissue descent and jowling.5 Medication-driven weight loss may further accentuate these changes in the lower face by affecting facial fat distribution.9
In a pivotal 12-month study of Restylane Shaype in the chin, 83% of people showed improved structure and definition at three months (66% at 12 months), and 84% of patients said they would agree to be treated with Restylane Shaype again.4 Furthermore, up to 97% of patients would recommend treatment with Restylane Shaype to a friend.4
Data in the jawline has also shown that Restylane Shaype was superior to no-treatment for restoring and enhancing jawline definition, with durable improvements maintained for up to two years.5 70% of patients reported improved overall satisfaction with their appearance and 82% noted the natural-looking results of the long-lasting treatment option.5 A further study of Restylane Shaype for the jawline shows over 92% would recommend the treatment to a friend and over 90% would choose to receive the treatment again.10
Restylane Shaype injections are administered with a new, next-generation syringe to enhance precision and control through its ergonomic design and optimized syringe-needle connection.1,2,11
|
“In my practice, I see many patients who are looking for effective, long-lasting facial enhancements to address their concerns around structure and facial balance. Having new innovations in injectable treatments that allow us to address these concerns with precision while maintaining natural-looking results is incredibly valuable. Restylane Shaype represents an exciting development for the field, combining a bone-mimicking hyaluronic acid gel with clinical evidence that demonstrates sustained, yet temporary, improvements in facial structure and definition.”
DR. OSVALDO VÁZQUEZ CEO OF SKIN GROUP AND HEAD OF THE DERMATOLOGY DEPARTMENT, HOSPITAL UNIVERSITARIO DR. JOSÉ ELEUTERIO GONZÁLEZ, MEXICO
|
|
Underpinning the Restylane range is a minimally modified HA gel that closely resembles naturally occurring HA. The gel is designed to deliver effective results with less product than other HA gels, and can be readily reversed, providing both performance and reassurance.12-16 Powered by Galderma’s new NASHA HD™ technology, Restylane Shaype is the firmest HA injectable gel available among market leaders in the facial filler market, with the highest G’ (measure of firmness) of the Restylane range.3
To support consistent, individualized use of Restylane Shaype in clinical practice, Galderma has developed the Shayping Technique™.17 The technique combines Galderma’s Assessment, Anatomy, Range, and Treatment (AART™) methodology and the Facial Assessment Scale (FAS), enabling healthcare professionals to systematically evaluate facial balance, helping to identify individual patient priorities and treatment goals.18,19 This assessment-led approach supports a broader understanding of lower face structure and creates definition for both the jawline and chin.4,5,18,19
|
“We’re thrilled to see this important milestone for Restylane Shaype in Mexico, especially with its first jawline approval worldwide. Restylane Shaype brings an additional innovative approach to structural enhancement in the lower face, expanding the possibilities for clinicians beyond what traditional HA fillers are designed to achieve. This approval further strengthens the Restylane portfolio and reflects Galderma’s commitment to advancing science-based treatments that address evolving patient needs and growing demand for facial balancing and harmonization.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and patient needs, including aesthetic concerns related to medication-driven weight loss and menopause. The distinctive bone-mimicking effect of Restylane Shaype demonstrates how the Restylane HA treatment range is uniquely positioned to support facial structure and skin health across all life stages, addressing changes that can affect bone density, structural support, and overall appearance.20-23
Supported by 30 years of innovation and more than 77 million treatments administered worldwide, Restylane has helped define the HA injectable category and continues to shape the future of aesthetic treatment.24-26 As patient expectations shift toward more effortless, always-on rejuvenation, Galderma’s ‘Wake Up To Restylane’ campaign positions Restylane as an everyday natural beauty ally for the face and other areas of the body, highlighting Galderma’s commitment to meeting emerging needs. Focused on the growing desire for natural, authentic results, the campaign underscores Restylane’s ability to deliver personalized outcomes that go beyond volumizing, helping people feel confident in their skin.27,28
About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.2,24,28 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.29-31 Powered by NASHA HD, NASHA®, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.3,32,33 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.24,34,35 Approved indications vary by market.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
- Restylane® Shaype™ Mexico Instructions for Use. November 2026.
- Restylane® EU Instructions for Use. July 2026.
- Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).
- Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
- Shridharani S, et al. Effectiveness and Safety of a High G′ Hyaluronic Acid Injectable for Jawline Definition: A Randomized Controlled Clinical Investigation. Dermatol Surg. 2026;00:1–8. doi.org/10.1097/DSS.0000000000005378.
- Galderma. Data on file. MA-53870. 2023. Restylane SHAYPE 43BBJ2001 Clinical Study Report.
- Galderma. Data on file. Restylane Market Research.
- Cole JB, et al. Human facial shape and size heritability and genetic correlations. Genetics. 2017; 205(2): 967-978. doi: 10.1534/genetics.116.193185.
- Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321.
- Galderma. Data on file. MA-62128. 2026. 43BBJ1911 Clinical Study Report.
- Galderma. Data on file. Dekra Restylane Next Generation Syringe Report.
- Hilton S, et al. Randomized, evaluator-blinded study comparing safety and effect of two hyaluronic acid gels for lips enhancement. Dermatol Surg. 2018;44(2):261–269. doi: 10.1097/DSS.0000000000001282.
- Nikolis A, et al. The CHEEKY study: effectiveness of cheek treatment with hyaluronic acid fillers HAVOL and HALYF. Poster presented at: AMWC, Monaco. 2022.
- Andriopoulos B, et al. Facial augmentation with hyaluronic acid fillers in an Asian population. Poster presented at AMWC, Monaco. 2019.
- Jones D, et al. A randomized, comparator-controlled study of HARC for cheek augmentation and correction of midface contour deficiencies J Drugs Dermatol. 2021;20;949–956. doi:10 .36849 /JDD .6191.
- Weiss R, et al. A randomized, controlled, evaluator-blinded, multi-center study of hyaluronic acid filler effectiveness and safety in lip fullness augmentation. Dermatol Surg. 2021;47(4):527–532. doi: 10.1097/DSS.0000000000002856.
- Lundgren B et al. Using a New Photo Scale to Compare Product Integration of Different Hyaluronan-Based Fillers After Injection in Human Ex Vivo Skin. J Drugs Dermatol. 2018;17:982–6. PMID: 30235386.
- Nikolis A, et al. The ARTIST post-marketing study: Evaluating a high G’ hyaluronic acid injectable for chin treatment in combination with other hyaluronic acid fillers for lower face and midface treatment. E-poster presented at AMWC; October 21-23, 2025; Dubai.
- Galderma. Data on file. AART Methodology Comprehensive Training Deck 2022.
- Kapoor KM, et al. Treating Aging Changes of Facial Anatomical Layers with Hyaluronic Acid Fillers. Clin Cosmet Investig Dermatol. 2021;14:1105-1118. doi: 10.2147/CCID.S294812.
- Fabi S, et al. The potential role of biostimulators/dermal fillers to address menopause related skin conditions. E-poster presented at IMCAS; October 21-23,2025; Dubai.
- Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. doi: 10.1111/jocd.70094.
- Galderma. Data on file. MA-56848. 2023. Technical data for Restylane SHAYPE.
- Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
- Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
- Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis.
- Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025.
- Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
- Edsman K, et al. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
- Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
- Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
- Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
- Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
- Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
- Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320.
Contacts
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
Tech-Inno Health Launches Branded Ingredients Business, Highlighting Urolithin A, S-Equol and Mulberry Leaf Extract
Tech-Inno Health Launches Branded Ingredients Business, Highlighting Urolithin A, S-Equol and Mulberry Leaf Extract
Tech-Inno Health Launches Branded Ingredients Business, Highlighting Urolithin A, S-Equol and Mulberry Leaf Extract
Research-led development, quality systems and industry collaboration underpin the company’s branded ingredients platform.
LOS ANGELES–(BUSINESS WIRE)–#Equol–Tech-Inno Health introduced its branded ingredients portfolio at SupplySide Global 2026 in Las Vegas. The portfolio features urolithin A, natural S-equol and mulberry leaf extract.
At the exhibition, Tech-Inno Health presented ingredient-specific research, quality and application information.
Tech-Inno Health defines branded ingredients as a long-term commitment to trust, built on ingredient-specific research, standardized manufacturing and verifiable evidence. Its approach combines research into mechanisms, efficacy and applications with defined specifications, safety dossiers, batch testing and traceability. Customers can review research data, quality documents and verification records to support product development and quality review.
Inaugural Branded Ingredients
- MitoIgnite® and MitoYouth® Urolithin A: Available for oral and topical applications, the range includes an oral-grade ingredient with at least 99% purity, an 80% topical powder and a 10% water-dispersible grade. Tech-Inno Health is exploring ribosome-related mechanisms and evaluating human efficacy at the formulation level, supported by patent applications and freedom-to-operate assessments for international markets.
- Disugar® Mulberry Leaf Extract: Available in 1% and 5% DNJ specifications. A database covering 72 batches from six growing regions, together with patented water-extraction and membrane-separation processes, supports raw-material consistency.
- NaturEQ™ S-Equol: Derived from a non-soy botanical source with at least 99% purity, the ingredient’s plant origin is verified through carbon-14 analysis, while chiral HPLC confirms its S-configuration. Tech-Inno Health has also conducted preclinical research related to pelvic floor health and filed patent applications in this area.
“We want customers to understand the research, quality and application evidence behind our branded ingredients,” said Kelly Y., head of the science department at Tech-Inno Health. “We aim to work with partners to turn research into practical product solutions and use application feedback to guide further research.”
For more information about the branded ingredients portfolio or partnership opportunities, visit https://techinnohealth.com/en/.
About Tech-Inno Health
Tech-Inno Health is a full-service supply chain solutions provider for the dietary supplement and functional food industries. Its end-to-end services span ingredient development, research, regulatory and patent strategy, formulation, quality control, manufacturing and finished-product delivery, supporting customers from product concept through commercialization. Its vision is “Make life ten years younger.”
Contacts
Tech-Inno Health
Jack Sun
sunjian@taiyi-nb.com


















